Evidence map›Paper›PMID 38585794›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Pre-exposure prophylaxis (PrEP) knowledge, use, and discontinuation among Lake Victoria fisherfolk in Uganda: a cross-sectional population-based study.

Kauthrah Ntabadde, Joseph Kagaayi, Victor Ssempijja, Xinyi Feng, Robert Kairania, Joseph Lubwama, Robert Ssekubugu, Ping Teresa Yeh, Joseph Ssekasanvu, Aaron A R Tobian and 10 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

Kauthrah NtabaddeJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Joseph KagaayiRakai Health Sciences Program, Kalisizo, Uganda.
Victor SsempijjaRakai Health Sciences Program, Kalisizo, Uganda.
Xinyi FengDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Robert KairaniaRakai Health Sciences Program, Kalisizo, Uganda.
Joseph LubwamaRakai Health Sciences Program, Kalisizo, Uganda.
Robert SsekubuguRakai Health Sciences Program, Kalisizo, Uganda.
Ping Teresa YehDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Joseph SsekasanvuJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Aaron A R TobianDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Caitlin E KennedyDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Lisa A MillsUnited States Centers for Disease Control and Prevention, Uganda, Division of Global HIV & TB, Kampala Uganda.
Stella AlamoUnited States Centers for Disease Control and Prevention, Uganda, Division of Global HIV & TB, Kampala Uganda.
Philip KreniskeCommunity Health and Social Sciences Department, Graduate School of Public Health and Health Policy, City University of New York (CUNY).
John SantelliDepartment of Population and Family Health and Pediatrics, Columbia University Mailman School of Public Health, New York, New York, USA.
Lisa J NelsonUnited States Centers for Disease Control and Prevention, Uganda, Division of Global HIV & TB, Kampala Uganda.
Steven J ReynoldsRakai Health Sciences Program, Kalisizo, Uganda.
Larry William ChangRakai Health Sciences Program, Kalisizo, Uganda.
Gertrude NakigoziRakai Health Sciences Program, Kalisizo, Uganda.
M Kate GrabowskiJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Johns Hopkins University · USRakai Health Sciences Program · UGCenters for Disease Control and Prevention · UGNational Institutes of Health · USColumbia University · USThe Graduate Center, CUNY · US

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Structural and Social Transitions Among Adolescents in Rakai (SSTAR)R01HD091003 · NICHD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SANTELLI, JOHN S. · 2017 to 2021
$3.7M
The role of penile bacteria and inflammation in HIV susceptibility; Rakai, UgandaR01AI123002 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI LIU, CINDY · 2016 to 2020
$3.3M
Neurologic Sequelae of HIV Subtype A and D Infection and ART Rakai UgandaR01MH099733 · NIMH · JOHNS HOPKINS UNIVERSITY · PI SACKTOR, NED C, WAWER, MARIA J · 2013 to 2017
$3.0M
Evaluating Demand Generation (Stylish Man) for HIV/Family Planning Services RakaiR01AI114438 · NIAID · JOHNS HOPKINS UNIVERSITY · PI WAWER, MARIA J · 2014 to 2017
$3.0M
RCT to reduce HIV acquisition and viral load among migrants, Rakai, UgandaR01MH115799 · NIMH · JOHNS HOPKINS UNIVERSITY · PI CHANG, LARRY WILLIAM, WAWER, MARIA J · 2018 to 2022
$2.9M
CHWs, mHealth, and Combination HIV Prevention in a Hotspot: A Randomized TrialR01MH107275 · NIMH · JOHNS HOPKINS UNIVERSITY · PI CHANG, LARRY WILLIAM · 2015 to 2019
$2.7M
Long-term impact of universal treatment and dolutegravir on population HIV virologic and incidence outcomes in Africa: The LONGVIEW StudyR01AI155080 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRABOWSKI, MARY KATHRYN · 2021 to 2024
$2.5M
Hard-to-Reach Populations: Implications for Ending the AIDS EpidemicR01AI143333 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CHANG, LARRY WILLIAM · 2019 to 2022
$2.4M
Penile Microbiome, Inflammation and HIV Susceptibility During Sexual Debut and Maturation Among Male AdolescentsR01AI128779 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TOBIAN, AARON A · 2017 to 2020
$2.1M
Multidisciplinary Research Training to Understand and Reduce HIV Incidence in UgandaD43TW010557 · FIC · JOHNS HOPKINS UNIVERSITY · PI CHANG, LARRY WILLIAM · 2018 to 2022
$1.6M
Understanding HIV risk and service use in hotspot Ugandan fishing communitiesR01MH105313 · NIMH · JOHNS HOPKINS UNIVERSITY · PI KENNEDY, CAITLIN E · 2015 to 2017
$1.1M
FIC NIH HHS D43 TW010557NIAAA NIH HHS K01 AA024068NIAID NIH HHS K01 AI125086NIAID NIH HHS K25 AI114461NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI114438NIAID NIH HHS R01 AI123002NIAID NIH HHS R01 AI128779NIAID NIH HHS R01 AI143333NIAID NIH HHS R01 AI155080NICHD NIH HHS R01 HD091003NIMH NIH HHS R01 MH099733NIMH NIH HHS R01 MH105313NIMH NIH HHS R01 MH107275NIMH NIH HHS R01 MH115799
6 · The paper itself

Abstract

Background: There are limited population-level data on the pre-exposure prophylaxis (PrEP) care continuum in eastern Africa. Here, we assessed the PrEP care continuum following PrEP rollout in a Ugandan community with ~40% HIV seroprevalence. Methods: We used cross-sectional population-based data collected between September 3 and December 19, 2018 from a Lake Victoria fishing community in southern Uganda to measure levels of self-reported PrEP knowledge, ever use, and discontinuation following 2017 PrEP rollout via a U.S. President's Emergency Plan for AIDS Relief (PEPFAR)-supported phased implementation program. Our analysis included HIV-seronegative persons reporting having ever received an HIV test result. We examined associations between demographic, behavioral, and health utilization factors with each outcome using age-adjusted modified Poisson regression. Results: There were 1,401 HIV-seronegative participants, of whom 1,363 (97.3%) reported ever receiving an HIV test result. Median age was 29 years (IQR: 23-36), and 42.3% (n=577) were women. Most (85.5%; n=1,166) participants reported PrEP knowledge, but few (14.5%; n=197) reported ever using PrEP. Among 375 (47.7%) men and 169 (29.3%) women PrEP-eligible at time of survey, 18.9% (n=71) and 27.8% (n=47) reported ever using PrEP, respectively. Over half (52.3%, n=103) of those who had ever used PrEP, self-reported current use. Conclusion: In this Lake Victoria fishing community, there were low levels of PrEP use despite high levels of PrEP awareness and eligibility, particularly among men. Efforts that enhance awareness of HIV risk and increase PrEP accessibility may help increase PrEP use among HIV-seronegative persons in African settings with high HIV burden.

Indexed as

AfricaHIVkey populationsLake Victoria fisherfolkpre-exposure prophylaxisPrEPUganda

Identifiers

PMID38585794
PMCPMC10996747
OpenAlexW4393355428

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.